| P/E (FY) | — | Sales (TTM) | $105.8M |
| Earnings (TTM) | -$829.6M | ROE | — |
| Net Margin | −891.60% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −2.36% |
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors as treatments for debilitating diseases in the United States. It markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic oHCM, and develops aficamten for HCM and omecamtiv mecarbil for heart failure with reduced ejection fraction. Its pipeline also includes ulacamten for heart failure with preserved ejection fraction and CK-089, a fast skeletal muscle compound.
| Market Cap | $9.89B | Trading Days | 5292 |
| 52W High | 88.31 |
| 52W Low | 32.89 |
| % Off High | −10.03% |
| YTD | 25.04% | 1Y | 116.90% |
| 3Y | 138.95% | 5Y | 173.40% |
| 10Y | 698.49% | Since incept. (ann.) | 2.08% |
License And Milestone Revenues 90% · Collaboration Revenues 10%
| Ann. Volatility (1Y) | 61.16% | Ann. Volatility (3Y) | 74.45% |
| Sharpe (1Y) | 1.56 | Sharpe (3Y) | 0.72 |
| Max Drawdown (1Y) | −15.01% | Max Drawdown (3Y) | −72.39% |
| Beta (3Y, vs SPY) | 1.19 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $10.01B | — |
| CORT | CORCEPT THERAPEUTICS INC | $10.11B | 114.9 |
| GPCR | Structure Therapeutics Inc. | $10.21B | — |
| IONS | IONIS PHARMACEUTICALS INC | $9.14B | — |
| NUVL | Nuvalent, Inc. | $9.01B | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| PTGX | Protagonist Therapeutics, Inc | $8.80B | — |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $12.00B | 34.5 |
